Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PR022 in mild-to-moderate atopic dermatitis
NCT03351777Phase 2Unknown
- Sponsor
- Realm Therapeutics
- Start
- Dec 2017
- Primary completion
- Apr 2018
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PR022 in atopic dermatitis (AD) (3 arms), sponsored by Realm Therapeutics. Primary endpoint: Eczema Area and Severity Index at 29 days. Status: unknown.
02
Drugs
PR022
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03351777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351777.